#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.
RSS   Newsletter   Contact   Advertise with us

Cellectar Biosciences appoints Igor Grachev as chief medical officer

Share on Twitter Share on LinkedIn
Christian Fernsby | Florham Park, N.J., USA | January 8, 2020
Cellectar BiosciencesCellectar Biosciences, a clinical-stage biopharmaceutical company, announced it has appointed Igor Grachev as chief medical officer.
Dr. Grachev brings nearly 20 years of industry experience to Cellectar having led clinical development programs at both multinational pharmaceutical and biotech organizations.

Dr. Grachev served as Global Development Leader and Head of Innovative Clinical Trials Initiative for TEVA Branded Specialty Pharmaceuticals.

He also had clinical development and medical affairs leadership roles for GE Healthcare, Novartis, GSK, Merck, Schering Plough, Sanofi-Aventis, and BioClinica.

Dr. Grachev is a former Assistant Professor of Radiology for SUNY Upstate Medical University and as a Fellow in Radiology at Massachusetts General Hospital, Harvard Medical School.